MediWound Launches Pivotal VALUE Trial for EscharEx® Treatment
In an exciting development for chronic wound care, MediWound Ltd. (NASDAQ: MDWD), a leader in enzymatic therapeutics, has begun the VALUE global Phase III pivotal trial. This trial focuses on evaluating the effectiveness and safety of EscharEx®, a new treatment for venous leg ulcers (VLUs).
Overview of the VALUE Trial
The VALUE study stands out as the most comprehensive investigation of its kind in more than a decade. Ofer Gonen, the CEO of MediWound, expressed pride in initiating this important study, highlighting the lack of new FDA-approved medications for VLUs since 1965. EscharEx® shows the promise of changing the standard treatment protocols for chronic wound debridement. Previous Phase II trials demonstrated EscharEx's efficacy in effectively and swiftly debriding chronic wounds, outshining SANTYL®, the market leader valued at over $375 million.
Trial Design and Objectives
This pivotal trial is designed as a global, multicenter, randomized, double-blind, placebo-controlled study. MediWound will conduct it across 40 sites in both the U.S. and Europe. The primary goal is to assess the efficacy and safety of EscharEx® in effectively debriding wounds and preparing them for healing. The study seeks to enroll 216 patients, randomly assigning them to receive either EscharEx® or a placebo, with treatment comprising up to eight daily applications over two weeks.
Key Endpoints and Monitoring
The co-primary endpoints for the VALUE trial include assessing both the rate of complete debridement and full wound closure. Secondary objectives encompass evaluating the presence of granulation tissue, the duration to achieve debridement and closure, and changes in wound size. Patient safety and product tolerability will be consistently monitored throughout the study. Importantly, an interim analysis will be conducted once 65% of participants have completed their treatments, enabling any necessary adaptive changes to the trial’s design.
Strategic Collaborations to Enhance the Study
To bolster the VALUE trial's success, MediWound has formed strategic collaborations with renowned partners such as Solventum, Mölnlycke, and MIMEDX. These partners will assist in providing advanced wound management products across all trial sites, aiming to ensure optimized patient outcomes.
Future Developments for MediWound
Beyond the VALUE trial, MediWound is also gearing up to launch a randomized, head-to-head Phase II study comparing EscharEx® with collagenase treatment for VLU patients within the next year. This trial is intended to support the submission of a Biologics License Application (BLA) for EscharEx® in the U.S., which will be crucial for the company’s overall commercialization strategy. Additionally, plans are being made for an adaptive design Phase II/III clinical trial targeting diabetic foot ulcers (DFUs), set to initiate in the upcoming years.
Understanding Venous Leg Ulcers
Venous leg ulcers impact approximately 2% of individuals over 65 years old, with over 1.5 million new cases appearing annually in the U.S. These ulcers arise primarily from chronic venous insufficiency, leading to large, shallow wounds on the lower legs that can result in severe pain, infection, and loss of mobility. Effective treatment options are desperately needed, with debridement being a critical step in managing these challenging wounds.
The Role of EscharEx®
EscharEx® is a breakthrough bioactive, multimodal therapy currently in advanced clinical stages, particularly aimed at treating chronic and hard-to-heal wounds. It comprises a concentrate of proteolytic enzymes, enriched with bromelain, designed for daily topical applications that are straightforward and user-friendly. Previous clinical trials have confirmed EscharEx’s safety, tolerability, and efficacy in the context of chronic wound care.
About MediWound Ltd.
MediWound (NASDAQ: MDWD) is recognized worldwide for its unique focus on enzymatic therapeutics aimed at non-surgical tissue repair. The company is dedicated to developing, manufacturing, and marketing innovative biologics that elevate current care standards, enhance patient experiences, and reduce healthcare costs overall.
Frequently Asked Questions
What is the VALUE trial about?
The VALUE trial is a Phase III study aimed at evaluating the efficacy and safety of EscharEx® for treating venous leg ulcers.
How many patients will be enrolled in the VALUE trial?
A total of 216 patients will be enrolled in the VALUE trial, randomly assigned to either EscharEx® or a placebo.
What are the primary endpoints of the VALUE trial?
The primary endpoints include the rates of complete debridement and full closure of the wound.
What are the expected outcomes of the VALUE trial?
The study aims to establish EscharEx® as a new standard in chronic wound treatment by demonstrating its efficacy and safety over established therapies.
Who can be contacted for more information about MediWound?
MediWound can be contacted via their investor relations email at ir@mediwound.com for inquiries.
